Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584844 | 0.81 | SCN9A (0.33) | SCN9APTGES | |
| SCHEMBL2575837 | 0.80 | SCN9A (0.34) | SCN9A | |
| SCHEMBL2369602 | 0.79 | BLM (0.39) | — | |
| Cadaverine Tartrate SCHEMBL13685410 | 0.77 | MLNR (0.31) | SCN9A | |
| SCHEMBL4663249 | 0.75 | SCN9A (0.33) | SCN9APTGES | |
| SCHEMBL4663242 | 0.74 | SMN1; SMN2 (0.33) | SCN9A | |
| SCHEMBL13685575 | 0.73 | ENPP2 (0.32) | SCN9A | |
| SCHEMBL2575840 | 0.69 | HTR2A (0.34) | SCN9A | |
| SCHEMBL2588786 | 0.69 | ESR1 (0.35) | SCN9A | |
| SCHEMBL507775 | 0.66 | HTR2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | SCN9A 1207/4885PTGES 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.